首页> 外文OA文献 >A Novel Hematopoietic Progenitor Cell (HPC) Mobilization Regimen, Utilizing Bortezomib and Filgrastim (G-CSF), for Patients Undergoing Autologous HPC Transplant (AHPCT) for Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL)

【2h】

A Novel Hematopoietic Progenitor Cell (HPC) Mobilization Regimen, Utilizing Bortezomib and Filgrastim (G-CSF), for Patients Undergoing Autologous HPC Transplant (AHPCT) for Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL)

机译：一种新型的造血祖细胞（HPC）动员方案，利用硼替佐米和非格司亭（G-CSF）用于接受自体HPC移植（AHPCT）的多发性骨髓瘤（MM）和非霍奇金淋巴瘤（NHL）患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Abhyankar Sunil; DeJarnette Shaun; Bunch Jennifer; Merkel Dean; Ganguly Siddhartha; Aljitawi Omar; Harvey Elizabeth; Daniels Kelly; McGuirk Joseph;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类
入库时间 2022-08-20 20:51:08

相似文献

外文文献
专利

1. Chemo-Mobilization of Autologous Hematopoietic Progenitor Cells (HPCs) with a Single Dose of Pegfilgrastim and Supplemental Filgrastim in Patients with Multiple Myeloma and Lymphoma: A Practical Schema [J] . McCallen Margaret R., Torloni A. Sergio, Jackson Marin L., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2015,第2Suppla1期

机译：在多发性骨髓瘤和淋巴瘤患者中，单剂量的pegfilgrastim和补充的filgrastim进行化学动员自体造血祖细胞（HPC）：
2. A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant [J] . Abhyankar Sunil, Lubanski Philip, DeJarnette Shaun, Journal of clinical apheresis. . 2016,第6期

机译：利用硼替佐米和非格司亭的新型造血祖细胞动员方案，用于自体移植患者
3. A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant [J] . Abhyankar Sunil, Lubanski Philip, DeJarnette Shaun, Journal of clinical apheresis. . 2016,第6期

机译：利用硼替佐米和非格司亭的新型造血祖细胞动员方案，用于自体移植患者
4. Strategies to Improve Outcomes in Multiple Myeloma: Preclinical Therapeutics Targeting MEK, HDAC and BCL-2 and Optimizing Autologous Hematopoietic Cell Transplantation [D] . Miller, Kevin Charles. 2020

机译：改善多发性骨髓瘤结果的策略：靶向MEK，HDAC和BCL-2的临床前治疗方法以及优化自体造血细胞移植
5. Safety and Efficacy of Upfront Plerixafor + G-CSF vs. Placebo + G-CSF for Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients ≥60 and 60 Years of Age with Non-Hodgkin’s Lymphoma or Multiple Myeloma [O] . Ivana N. Micallef, Patrick J. Stiff, Edward A. Stadtmauer, -1

机译：60岁以上和60岁以下非霍奇金淋巴瘤或多发性骨髓瘤患者中前者Plerixafor + G-CSF与安慰剂+ G-CSF调动CD34 +造血祖细胞的安全性和有效性
6. Chemo-Mobilization of Autologous Hematopoietic Progenitor Cells (HPCs) with a Single Dose of Pegfilgrastim and Supplemental Filgrastim in Patients with Multiple Myeloma and Lymphoma: A Practical Schema [O] . McCallen Margaret R., Torloni A. Sergio, Jackson Marin L., 2015

机译：在多发性骨髓瘤和淋巴瘤患者中，单剂量pegfilgrastim和补充的filgrastim进行化学动员自体造血祖细胞（HPC）：

A Novel Hematopoietic Progenitor Cell (HPC) Mobilization Regimen, Utilizing Bortezomib and Filgrastim (G-CSF), for Patients Undergoing Autologous HPC Transplant (AHPCT) for Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL)

著录项

相似文献

相关主题

期刊订阅